NCT02234986View on ClinicalTrials.gov

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Advanced Adult Hepatocellular CarcinomaAdvanced Fibrolamellar Carcinoma
Interventions
DRUG

ENMD-2076

250 mg oral dose, once daily (QD) for 28 day cycles

Trial Locations (5)

10065

Casi Site 01, New York

75231

CASI Site 05, Dallas

80045

CASI Site 04, Aurora

94158

CASI Site 03, San Francisco

01003

CASI Site 02, Boston

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY

NCT02234986 - A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | Biotech Hunter | Biotech Hunter